Prelude Therapeutics (PRLD)
(Delayed Data from NSDQ)
$3.87 USD
0.00 (0.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $3.88 +0.01 (0.26%) 7:32 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Income Statements
Fiscal Year end for Prelude Therapeutics Incorporated falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 132 | 124 | 114 | 59 | 28 |
Income After Depreciation & Amortization | -132 | -124 | -114 | -59 | -28 |
Non-Operating Income | 10 | 8 | 2 | 2 | 1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -122 | -115 | -112 | -57 | -28 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -122 | -115 | -112 | -57 | -28 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -122 | -115 | -112 | -57 | -28 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -135 | -120 | -111 | -58 | -28 |
Depreciation & Amortization (Cash Flow) | -2 | 4 | 2 | 1 | 0 |
Income After Depreciation & Amortization | -132 | -124 | -114 | -59 | -28 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 60.36 | 47.37 | 46.05 | 12.48 | NA |
Diluted EPS Before Non-Recurring Items | -2.02 | -2.44 | -2.43 | -4.56 | NA |
Diluted Net EPS (GAAP) | -2.02 | -2.44 | -2.43 | -4.56 | NA |
Fiscal Year end for Prelude Therapeutics Incorporated falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 37.38 | 33.38 | 32.40 | 29.11 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -37.38 | -33.38 | -32.40 | -29.11 |
Non-Operating Income | NA | 4.30 | 2.78 | 1.97 | 1.40 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -33.08 | -30.61 | -30.43 | -27.72 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -33.08 | -30.61 | -30.43 | -27.72 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -33.08 | -30.61 | -30.43 | -27.72 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 60.36 | 67.64 | 56.24 | 47.74 |
Diluted EPS Before Non-Recurring Items | NA | -0.47 | -0.45 | -0.54 | -0.58 |
Diluted Net EPS (GAAP) | NA | -0.45 | -0.45 | -0.54 | -0.58 |